What Does the Prostate Cancer CDMRP Do And Why Is It So Important?

The problems created by Senator McCain continue to be ever present.  Our friend, Senator Durbin has asked that we provide his office with additional background about the military nature of the research performed by the Congressionally Directed Medical Research Programs (CDMRP), including the Prostate Cancer Research Program (PCRP). In addition there is a very misguided [...]

Please Reach Out To Senator Pat Roberts If You Live In Kansas

I have just received an update on Senator McCain's amendment.  According to Senator Pat Robert’s office they need to hear from more individuals from Kansas on opposing #1482 (the McCain amendment)so if it comes up they can let the Senator know and inform his position. If you live in Kansas, have family in Kansas or friends [...]

We Need Your Story To Save The CDMRP – If You Have Benefitted From Xfigo, Xtandi or Zytiga Let Me Know

Most people don't know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY.  Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available? The DOD PCRP is directly [...]

CDMRP PCRP Passes A Hurdle For Its 2016 Funding

About one hour ago I received some good news from Zero pertaining to the Congressionally Directed Medical Research Program.   The HAC-D report of the FY2016 Defense Appropriations Bill has the Prostate Cancer Research Program funded at $80M. The full bill can be seen here : http://appropriations.house.gov/uploadedfiles/hrpt-114-hr-fy2016-defense.pdf and the CDMRP numbers are found on page 273. The [...]

By |2020-02-04T08:47:04-05:00June 2nd, 2015|Advanced Prostate Cancer, Advocacy, DOD, Uncategorized|0 Comments

Radiologic Progression Free Survival Might Predict Treatment Response and Survival

In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]

Go to Top